A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma. (NCT03539744)

🧪 Interventions in This Study

• Pomalidomide (DRUG)
• Dexamethasone (DRUG)
• Venetoclax (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (180 Sites)

Showing the first 25 of 180 sites.

• Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407 — Tucson, Arizona
• VA Central California Health Care System /ID# 200047 — Fresno, California
• University of California, Los Angeles /ID# 171524 — Los Angeles, California
• Rocky Mountain Regional VA Medical Center/Eastern Colorado Health Care System /ID# 222904 — Aurora, Colorado
• Mayo Clinic /ID# 200075 — Jacksonville, Florida
• Cleveland Clinic Florida /ID# 208884 — Weston, Florida
• Duplicate_Norton Cancer Institute /ID# 200834 — Louisville, Kentucky
• University of Maryland, Baltimore /ID# 217422 — Baltimore, Maryland
• Boston Medical Center /ID# 223606 — Boston, Massachusetts
• Barbara Ann Karmanos Cancer In /ID# 201377 — Detroit, Michigan
• Duplicate_Henry Ford Hospital /ID# 171531 — Detroit, Michigan
• Mayo Clinic - Rochester /ID# 201091 — Rochester, Minnesota
• Columbia University Medical Center /ID# 200715 — New York, New York
• Fairview Hospital - Moll Pavilion /ID# 208919 — Cleveland, Ohio
• Cleveland Clinic Main Campus /ID# 202247 — Cleveland, Ohio
• UPMC Hillman Cancer Ctr /ID# 200063 — Pittsburgh, Pennsylvania
• MD Anderson Cancer Center at Texas Medical Center /ID# 200060 — Houston, Texas
• Huntsman Cancer Institute /ID# 218406 — Salt Lake City, Utah
• VA Puget Sound Health Care System /ID# 222708 — Seattle, Washington
• Liverpool Hospital /ID# 202431 — Liverpool, New South Wales
• Sydney Adventist Hospital /ID# 222874 — Wahroonga, New South Wales
• Wollongong Hospital /ID# 205545 — Wollongong, New South Wales
• ICON Cancer Care - Townsville /ID# 206565 — Hyde Park, Queensland
• Icon Cancer Centre /ID# 205663 — South Brisbane, Queensland
• The Queen Elizabeth Hospital /ID# 202432 — Woodville South, South Australia

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Multiple Myeloma

• Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
• A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
• Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
• MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
• A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
• A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey

Explore by condition: All Multiple Myeloma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.